MedDataX Logo

Liquid Biopsy Collection Study

NCT ID: NCT06068348

Last Updated: 2024-12-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-07

Study Completion Date

2025-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to develop a liquid biopsy approach for detection of circulating tumor cells (CTC) that could be used in place of the more invasive and potentially risky methods of tissue biopsy. The aims of the project are: (a) determine whether the Chaperonin-Containing TCP-1 (CCT) chaperonin can used to identify rare cancer cells in blood, and (b) establish whether the cancer cells detected using the CCT chaperonin for identification have invasive or metastatic potential.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chaperonin-Containing TCP-1 Circulating Tumor Cells CCT CTC

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female
* Age greater than or equal to 18 and less than or equal to 80 years.

Exclusion Criteria

* Adults unable to give informed consent
* Individuals who are not yet adults (infants, children, teenagers; under the age of 18)
* Individuals who weigh less than 110 lbs (as standard clinically advised to not give blood)
* Pregnant women (due to hormonal changes in blood)
* Prisoners
* Persons reporting a current microbial (bacterial, viral, or fungal) infections
* Persons reporting that they are current taking antibiotic medications
* Persons with body temperatures above 99oF (indicating a fever)
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Central Florida

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Annette Khaled, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Central Florida

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Central Florida

Orlando, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STUDY00003221

Identifier Type: -

Identifier Source: org_study_id